Press releases
February 28, 2022
Montagu as new investor
February 28, 2022
HTL announces that Montagu, a leading private equity firm, has acquired a majority stake of HTL previously held by Bridgepoint. The other minority shareholders, Naxicap and Téthys Invest, will keep their shares in the company.
The arrival of this new shareholder symbolizes the international success of a company that has become the world leader in the development and production of pharmaceutical grade biopolymers.
To see our most recent news,
Read more
news from us
-
Articles July 5, 2024HTL Biotechnology Secures Medical Device Registration in China
Sodium DNA Raw Material Main Document (Polynucleotides) registered as a medical device (number M2024199-000) in China.
-
Articles June 21, 2024HTL Biotechnology at CPHI China 2024
CPHI China is one of Asia’s leading Pharma events for trading and networking with 3,500+ exhibitors and 90,000+ professionals from the pharmaceutical industry,
-
Articles June 13, 2024Discover our Quality Policy
At HTL Biotechnology, we believe in going beyond together to achieve the highest quality standards.